Keya Medical, a leading medical technology manufacturer, showcased its deep learning-based diagnostic and treatment solutions at the World Artificial Intelligence Conference 2021 (WAIC 2021) held in Shanghai from July 7-10. Themed “Intelligent Connectivity, Inspirational Cities,” the conference brought together over 300 AI companies to highlight the latest developments in the industry and encourage global collaboration to enhance the common welfare.
During the conference, Keya Medical showcased its flagship product DeepVessel FFR, the first AI-empowered Class III medical device approved by the National Medical Products Administration (NMPA) for commercialization in China. DeepVessel FFR uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries to accurately diagnose whether patients have suffered from myocardial ischemia, based on patients’ computed tomography angiography (CTA) images. Keya Medical has completed 13 clinical trials involving the validation of DeepVessel FFR in collaboration with top medical schools in China, and the software has been implemented in over 1,000 Chinese hospitals.
Dr. Qi Song and colleagues at the Edison Medical Artificial Intelligence Summit at WAIC 2021 hosted by GE Healthcare.
Dr. Qi Song, CEO of Keya Medical, was invited to attend the Edison Medical Artificial Intelligence Summit hosted by GE Healthcare. During the summit, Dr. Song and other medical AI industry elites discussed the development trends in the digital healthcare industry. At the end of the meeting, Dr. Song and his co-presenters formed a strategic collaboration with GE Healthcare, signing the GE Healthcare Edison Digital Ecological Strategic Cooperation Agreement to accelerate the implementation and adoption of AI-enabled precision medicine. The cooperation agreement aims to encourage collaboration to create a bright future for digital medical ecology, promote the integration of AI and high-quality medical services, and better serve patients.
As an international leader in the medical AI industry, Keya Medical adheres to the corporate philosophy of empowering the healthcare industry with diagnostic and treatment solutions that solve real clinical challenges. Keya Medical will continue collaborating with healthcare organizations to develop deep learning-based solutions that will cover all stages in the care continuum, including early screening, diagnosis, treatment, and post-treatment maintenance to transform care delivery.
About Keya Medical
Keya Medical Technology Co. Ltd. is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Since 2016, Keya Medical has collaborated with more than 725 hospitals to improve diagnostics, care processes, and clinical outcomes. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.